United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - tablet, extended release - 324 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (seedosage and administration ), then quinidine gluconate should be discontinued. chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

eon labs, inc. - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine sulfate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgement of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures (e.g.,

United States - English - NLM (National Library of Medicine)

eywa pharma inc - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after

United States - English - NLM (National Library of Medicine)

epic pharma, llc - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see dosage and administration), then quinidine sulfate should be discontinued. chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgement of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures (e.g., use of other drugs to control the ventricular rate) have been found to be inadequate. in patients with histories of frequent symptomatic episodes of atrial fibrillation/flutter, the goal of therapy should be an increase in the average time between episodes. in most patients, the tachyarrhythmia will recur during therapy, and a single recurrence should not be interpreted as therapeutic failure. quinidine sulfate is also indicated for the suppression of recurrent documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are lifethreatening. because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recommended, and treatment of patients with asymptomatic ventricular premature contractions should be avoided. where possible, therapy should be guided by the results of programmed electrical stimulation and/or holter monitoring with exercise. antiarrhythmic drugs (including quinidine sulfate) have not been shown to enhance survival in patients with ventricular arrhythmias. quinidine sulfate is also indicated in the treatment of life-threatening plasmodium falciparum malaria . quinidine is contraindicated in patients who are known to be allergic to it, or who have developed thrombocytopenic purpura during prior therapy with quinidine or quinine. in the absence of a functioning artificial pacemaker, quinidine is also contraindicated in any patient whose cardiac rhythm is dependent upon a junctional or idioventricular pacemaker, including patients in complete atrioventricular block. quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent.

United States - English - NLM (National Library of Medicine)

carilion materials management - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 324 mg - conversion of atrial fibrillation/flutter in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine gluconate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time (see dosage and administration ), then quinidine gluconate should be discontinued. reduction of frequency of relapse into atrial fibrillation/flutter chronic therapy with quinidine gluconate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine gluconate. the increased risk of death should specifically be considered. quinidine gluconate should be used only after alternative meas

United States - English - NLM (National Library of Medicine)

carilion materials management - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg - in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response, quinidine sulfate is indicated as a means of restoring normal sinus rhythm. if this use of quinidine sulfate does not restore sinus rhythm within a reasonable time (see ), then quinidine sulfate should be discontinued. dosage and administration chronic therapy with quinidine sulfate is indicated for some patients at high risk of symptomatic atrial fibrillation/flutter, generally patients who have had previous episodes of atrial fibrillation/flutter that were so frequent and poorly tolerated as to outweigh, in the judgment of the physician and the patient, the risks of prophylactic therapy with quinidine sulfate. the increased risk of death should specifically be considered. quinidine sulfate should be used only after alternative measures ( use of other drugs to control the ventricular rate) have been found to be inad

United States - English - NLM (National Library of Medicine)

eli lilly and company - quinidine gluconate (unii: r6875n380f) (quinidine - unii:itx08688jl) - quinidine gluconate 80 mg in 1 ml - treatment of malaria — quinidine gluconate injection is indicated for the treatment of life–threatening plasmodium falciparum malaria. conversion of atrial fibrillation/flutter — quinidine gluconate injection is also indicated (when rapid therapeutic effect is required, or when oral therapy is not feasible) as a means of restoring normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter whose symptoms are not adequately controlled by measures that reduce the rate of ventricular response. if this use of quinidine gluconate does not restore sinus rhythm within a reasonable time, then its use should be discontinued. treatment of ventricular arrhythmias — quinidine gluconate injection is also indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life–threatening. because of the proarrhythmic effects of quinidine, its use with ventricular arrhythmias of lesser severity is generally not recomme

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - quinidine sulfate (unii: j13s2394he) (quinidine - unii:itx08688jl) - quinidine sulfate 200 mg